Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
28 Septembre 2023 - 1:00PM
Business Wire
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a
clinical-stage company leveraging its hydrogen sulfide platform to
develop next-generation therapies targeting pain and inflammation,
is pleased to announce Health Canada’s approval to initiate the
pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s
faster-absorbing formulation for acute pain. Set to commence in
October, the purpose of the study is to inform the doses for the
Phase II trial.
“With this approval, we’re excited to start the first-in-human
study of otenaproxesul’s new formulation -- and to be on track to
launch the Phase II trial in calendar Q1 2024,” commented Dan
Legault, Antibe’s CEO. “We look forward to updating our
shareholders with the PK/PD results later in the upcoming
quarter.”
About Antibe Therapeutics Inc.
Antibe is a clinical-stage biotechnology company leveraging its
proprietary hydrogen sulfide platform to develop next-generation
therapies to target inflammation arising from a wide range of
medical conditions. The Company’s current pipeline includes assets
that seek to overcome the gastrointestinal ulcers and bleeding
associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”).
Antibe’s lead drug, otenaproxesul, is in clinical development as a
safer alternative to opioids and today’s NSAIDs for acute pain.
Antibe’s second pipeline drug, ATB-352, is being developed for a
specialized pain indication. The Company’s next target is
inflammatory bowel disease (“IBD”), a condition long in need of
safer, more effective therapies. Learn more at antibethera.com.
Forward Looking Information
This news release includes certain forward-looking statements
under applicable securities laws, which may include, but are not
limited to, the anticipated scope, timing, duration and completion
of certain of the Company’s clinical trial programs and studies
including the PK/PD study and its results, the Phase II trial and
the anticipated timing for seeking market approval for certain of
the Company’s drugs and therapies for certain additional
indications. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “will”, “anticipate”,
“believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and
similar wording. Forward-looking statements involve known and
unknown risks and uncertainties that could cause actual results,
performance, or achievements to differ materially from those
expressed or implied in this news release. Factors that could cause
actual results to differ materially from those anticipated in this
news release include, but are not limited to, the Company’s
inability to timely execute on its business strategy and timely and
successfully complete its clinical trials and studies, the
Company’s inability to obtain the necessary regulatory approvals
related to its activities, risks associated with drug development
generally and those risk factors set forth in the Company’s public
filings made in Canada and available on sedar.com. The Company
assumes no obligation to update the forward-looking statements or
to update the reasons why actual results could differ from those
reflected in the forward-looking statements except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230928171285/en/
Antibe Therapeutics Inc. Christina Cameron VP Investor Relations
+1 416-577-1443 christina@antibethera.com
Antibe Therapeutics (TSX:ATE)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Antibe Therapeutics (TSX:ATE)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024